In silico theoretical molecular modeling for Alzheimer's disease: The nicotine-curcumin paradigm in neuroprotection and neurotherapy

International Journal of Molecular Sciences

Volumn 12, Issue 1, 2011, Pages 694-724

  Kumar, Pradeep ^a   Pillay, Viness ^a   Choonara, Yahya E ^a   Modi, Girish ^a   Naidoo, Dinesh ^a   du Toit, Lisa C ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Alzheimer's disease; Amyloid ; Artificial neural networks; Central composite design; Constraint optimization; Curcumin; Docking; Isobolographic analysis; Ligand protein complexes; Molecular mechanics; Nicotine; Protein; Synergism

Indexed keywords

2,9 DIMETHYL 1,10 PHENANTHROLINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APIGENIN; BENZOPHENONE DERIVATIVE; CONGO RED; CURCUMIN; DIHYDROXYBENZOPHENONE; GLYCOSYLATED NORNICOTINE; HEXAMETHYLPYRIDINIUM; INDOMETACIN; MOLECULAR SCAFFOLD; NORNICOTINE; POLYSTYRENESULFONIC ACID; PYRIDINIUM DERIVATIVE; THIOFLAVINE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; NICOTINE;

ACCURACY; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; ARTIFICIAL NEURAL NETWORK; BINDING AFFINITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; ISOBOLOGRAPHIC ANALYSIS; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOLECULAR MODEL; NEUROPATHOLOGY; NEUROPROTECTION; OLIGOMERIZATION; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; SENSITIVITY ANALYSIS; STOCHASTIC MODEL; THEORETICAL MODEL; ANALOGS AND DERIVATIVES; BIOLOGY; HUMAN; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COMPUTATIONAL BIOLOGY; CURCUMIN; HUMANS; NEUROPROTECTIVE AGENTS; NICOTINE;

EID: 79251636605     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12010694     Document Type: Article

References (42)

1. Abbott, A. The plaque plan. Nature 2008, 456, 161-164.
2. Choonara, Y.E.; Pillay, V.; du Toit, L.C.; Modi, G.; Naidoo, D.; Ndesendo, V.M.; Sibambo, S.R. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int. J. Mol. Sci. 2009, 10, 2510-2557.
3. Popovic, N.; Brundin, P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm. 2006, 314, 120-126.
4. Nowacek, A.; Kosloski, L.M.; Gendelman, H.E. Neurodegenerative disorders and nanoformulated drug development: Executive summary. Nanomedicine 2009, 4, 541-555.
5. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6, 487-498.
6. Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997, 20, 154-159.
7. Mucke, L. Alzheimer's disease. Nature 2009, 461, 895-897.
8. Hamaguchi, T.; Ono, K.; Yamada, M. Curcumin and Alzheimer's Disease. CNS Neurosci. Therap. 2010, doi:10.1111/j.1755-5949.2010.00147.x.
9. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; Cole, G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280, 5892-5901.
10. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8, 101-112.
11. Hamaguchi, T.; Ono, K.; Yamada, M. Anti-amyloidogenic therapies: Strategies for prevention and treatment of Alzheimer's disease. Cell Mol. Life Sci. 2006, 63, 1538-1552.
12. Dickerson, T.J.; Janda, K.D. Glycation of the amyloid β-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2003, 100, 8182-8187.
13. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
14. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
15. Glabe, C.C. Amyloid accumulation and pathogenesis of Alzheimer's. Subcell Biochem. 2005, 38, 167-177.
16. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C.L.; Beyreuther, K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J. Mol. Biol. 1992, 228, 460-473.
17. Fraser, P.E.; McLachlan, D.R., Surewicz, W.K.; Mizzen, C.A.; Snow, A.D.; Nguyen, J.T.; Kirschner, D.A. Conformation and fibrillogenesis of alzheimer Aβ peptides with selected substitution of charged residues. J. Mol. Biol. 1994, 244, 64-73.
18. Woods, S.J.; MacKenzie, L.; Maleeff, B.; Hurle, M.R.; Wetzel, R. Selective inhibition of Abeta fibril formation. J. Biol. Chem. 1996, 271, 4086-4092.
19. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C.L.; Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 1991, 218, 149-163.
20. Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S.; Iwatsubo, T.; Goedert, M.; Hasegawa, M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 2005, 280, 7614-7623.
21. Kuner, P.; Bohrmann, B.; Tjernberg, L.O.; Naslund, J.; Huber, G.; Celenk, S.; Gruninger-Leitch, F.; Richards, J.G.; Jakob-Roetne, R.; Kemp, J.A.; Nordstedt, C. Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic smail molecule ligands. J. Biol. Chem. 2000, 275, 1673-1678.
22. Chirita, C.N.; Congdon, E.E.; Yin, H.; Kuret, J. Triggers of full-length tau aggregation: A role for partially folded intermediates. Biochemistry 2005, 44, 5862-5872.
23. Netland, E.E.; Newton, J.L.; Majocha, R.E.; Tate, B.A. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol. Aging 1998, 19, 201-204.
24. Sabate, R.; Gallardo, M.; Estelrich, J. Temperature dependence of the nucleation constant rate in beta amyloid fibrillogenesis. Int. J. Biol. Macromol. 2005, 35, 9-13.
25. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282, 10311-10324.
26. Cabaleiro-Lago, C.; Quinlan-Pluck, F.; Lynch, I.; Dawson, K.A.; Linse, S. Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem. Neurosci. 2010, 1, 279-287.
27. Weber, I.T.; Harrison, R.W. Molecular mechanics calculations on protein-ligand complexes. Persp. Drug Disc. Des. 1998, 9-11, 115-127.
28. Rotthäuser, B.; Krausb, G.; Schmidt, P.C. Optimization of an effervescent tablet formulation containing spray dried l-leucine and polyethylene glycol 6000 as lubricants using a central composite design. Eur. J. Pharm. Biopharm. 1998, 46, 85-94.
29. He, G.; Xuan, G.; Ruan, H.; Chen, Q.; Xu, Y. Optimization of angiotensin I-converting enzyme (ACE) inhibition by rice dregs hydrolysates using response surface methodology. J. Zhejiang Univ. SCI. 2005, 6B, 508-513.
30. Liu, T.; Zhang, C.; Yang, G; Wua, J.; Xie, G.; Zeng, H.; Yin, C.; Liu, T. Central composite design-based analysis of specific leaf area and related agronomic factors in cultivars of rapeseed (Brassica napus L.). Field Crop Res. 2009, 111, 92-96.
31. Djoudi, W.; Aissani-Benissad, F.; Bourouina-Bacha, S. Optimization of copper cementation process by iron using central composite design experiments. Chem. Engl. J. 2007, 133, 1-6.
32. Formaggio, E.; Fazzini, F.; Dalfini, A.C.; Di Chio, M.; Cantù, C.; Decimo, I.; Fiorini, Z.; Fumagalli, G.; Chiamulera, C. Nicotine increases the expression of neurotrophin receptor tyrosine kinase receptor A in basal forebrain cholinergic neurons. Neuroscience 2010, 166, 580-589.
33. Flood, J.F.; Roberts, E.; Sherman, M.A.; Kaplan, B.E.; Morley, J.E. Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid beta protein. Proc. Natl. Acad. Sci. USA 1994, 91, 380-384.
34. Frautschy, S.A.; Cole, G.M. Why pleiotropic interventions are needed for alzheimer's disease? Mol. Neurobiol. 2010, 41, 392-409.
35. RCSB Protein Data Bank. Available online: www.pdb.org (accessed on 18 April 2010).
36. Chemical Entities of Biological Interest (ChEBI). Available online: www.ebi.ac.uk/chebi (accessed on 22 April 2010).
37. The TDR Targets Database v4. Available online: www.tdrtargets.org (accessed on 22 April 2010)
38. PubChem structure search. Available online: www.pubchem.ncbi.nlm.nih.gov (accessed on 22 April 2010).
39. Niculescu, S.P. Artificial neural networks and genetic algorithms in QSAR. J. Mol. Struct. Theochem. 2003, 622, 71-83.
40. Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
41. Hayes, M.J.; Stein, M.; Weiser, J. Accurate calculations of ligand binding free energies. J. Phys. Chem. 2004, 108, 3572-3580.
42. Loewe, S.; Muchnik, H. Effect of combinations: Mathematical basis of problem. Arch. Exp. Pathol. Pharmacol. 1926, 114, 313-326.